How did Portugal become a global leader in the decriminalization of substances? Professor of Law João Taborda da Gama shares his insights. Learn how changes in the law impact a nation’s health and what Ukraine can adopt from this experience to help veterans.
João Taborda da Gama is a lawyer, professor of law and public policy, a partner at Gama Glória, and the author of the book Direito Psicadélico (2023). He advises governments and international organizations on the regulation of controlled substances.
Watch the recording of the webinar “Legal and Regulatory Aspects of Introducing Psychedelic-Assisted Therapy in Europe” with Marion Haberkamp. Learn how the EU regulatory system works, how it differs from the FDA’s approach, and what steps have already been taken in Germany regarding the use of psilocybin.
Stay connected and subscribe to UPRA’s YouTube channel: @ukrainianpsychedelicresearcha
How can one LEGALLY use PSYCHEDELICS for medical treatment around the world? Pavel Pachta Is it possible to legally use psychedelics to treat mental disorders? In this video, an expert examines the legal aspects of psychedelic-assisted therapy through the lens of international law and successful case studies from European countries.
In this episode, you’ll learn:
What does the 1971 UN Convention actually allow regarding psilocybin and MDMA?
Under what conditions can a patient receive such treatment?
Who is authorized to prescribe psychedelics, and where must the sessions take place?
A detailed analysis of the Czech Republic’s case: from physician qualifications to specific dosage limits.
How can the state regulate the circulation of these substances without restricting patients’ rights to innovative therapy?
On 7 May 2026, policymakers, researchers, clinicians, people with lived experience, and civil society organisations gathered in Brussels for the inaugural meeting of PAREA.
In this interview, PAREA founder, Tadeusz Hawrot, reflects on the policy landscape, regulatory challenges, and the future of access to these emerging treatments in the EU.
The topics in this episode:
Introduction to PAREA
Why is Europe Lagging Behind the USA in Psychedelic Science?
Which Psychedelic Substances Have the Greatest Potential to Become Medicines in the EU?
Is There Potential in National Legislation, Such as in the Czech Republic?
What Should Be Done About the Grey Areas of Psychedelic Treatment?
How Can Professionals Be Trained in Psychedelic Treatment?
Interview: Péter Sárosi
Video: István Gábor Takács
How could evidence-based psychedelic therapies help address war-related mental health challenges in Ukraine, particularly PTSD among veterans? This was the main question of the European Parliament event held on 6 May, which Drugreporter captured on video in its entirety.
Lauren Macdonald shares her testimony at the PsyPal launch event. Witness her personal journey from cancer patient to advocate for psilocybin therapy.
Maryam took part in a Compass Pathways phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression. The testimonial was made during the MEP Action Group for the Medical Use of Psychedelics meeting "Innovating Mental Health in the EU Pharma Legislation.
There is a growing belief that research around the potential of psychedelics is finally making key policymakers within the European Parliament stand up and take notice. With organisations like PAREA now facilitating meaningful conversations which could lead to a shift in perception, how could the EU take a central role in driving psychedelic healthcare to become a reality across Europe? PSYCH Symposium's panel of change-makers and MEPs discussed how far the needle has moved and which actions are needed to bring about an evolution in approach.
On 6th December, PAREA organized our first policy meeting in the European Parliament, looking at the basic ingredients of psychedelic novel treatments captured in the event’s title: “Psychedelic-assisted therapies in the treatment of brain disorders”.
To further shape the discussions on the responsible and safe rollout of those treatments in the future, at the event, PAREA launched “An appeal to the European Union institutions and Member States”. You can learn more details here: https://parea.eu/eu-parliament-appeal
Clinical Trial participant on AWAKN’s Phase IIa study examining MDMA psychotherapy for Alcohol Use Disorder.
On the 31st of August 2022, our speakers dug deep into topics like how psychedelic-assisted therapy will become a reality and what the legislative and regulatory roadblocks will be.
This video was recorded at the 8th Congress of the European Academy of Neurology in Vienna
This video was recorded at the 8th Congress of the European Academy of Neurology in Vienna
This video was recorded at the 8th Congress of the European Academy of Neurology in Vienna